Identification of responders to novel treatments among children with severe asthma

What is it about?

We analysed through a metabolomic approach urine samples collected in children and adolescents with severe asthma before starting omalizumab. We found that patients who respond to omalizumab show a different metabolomic urinary profile at baseline with respect to non-responders

Featured Image

Why is it important?

Our study paves the way to a possible a-priori identification of patients most likely to benefit from omalizumab, leading to a truly personalised therapeutic approach.